Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
18 hedge funds and large institutions have $3.72M invested in Interpace Biosciences, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
57% more capital invested
Capital invested by funds: $2.37M → $3.72M (+$1.36M)
38% more funds holding
Funds holding: 13 → 18 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$660K |
| 3 |
VF
Virtu Financial
New York
|
+$158K |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$110K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$59.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$72K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$725 |
| 3 |
Morgan Stanley
New York
|
-$725 |
IDXG Hedge Fund Activity: Q4 2017 in Review
18 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2017, worth a combined $3.72M — up 57% from $2.37M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IDXG positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.59M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $72K sold.
- 18 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2017, up from 13 in Q3 2017.
- Funds reported $3.72M of Interpace Biosciences, Inc. Common Stock stock for Q4 2017, up 57% quarter-over-quarter.
- 7 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2017 and 2 closed out, a net change of +5 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2017 was Sabby Management, an estimated $1.59M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2017 was Two Sigma Securities, an estimated $72K sold.
Based on aggregated 13F filings for Q4 2017.